Gamida Cell Ltd. (NASDAQ:GMDA – Get Rating) has been assigned an average rating of “Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued a report on the stock in the last year is $13.83.
A number of research analysts recently weighed in on the stock. Piper Sandler reduced their price objective on shares of Gamida Cell from $13.00 to $6.00 in a research note on Tuesday, May 10th. JMP Securities restated a “buy” rating and set a $17.00 price target on shares of Gamida Cell in a research report on Thursday, June 2nd.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its position in Gamida Cell by 539.0% in the first quarter. Bank of America Corp DE now owns 15,214 shares of the company’s stock worth $63,000 after acquiring an additional 12,833 shares in the last quarter. OLD National Bancorp IN purchased a new position in Gamida Cell in the second quarter worth $57,000. GSA Capital Partners LLP purchased a new position in Gamida Cell in the fourth quarter worth $83,000. Mariner LLC grew its position in Gamida Cell by 8.3% in the first quarter. Mariner LLC now owns 621,334 shares of the company’s stock worth $2,579,000 after acquiring an additional 47,587 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Gamida Cell by 12.8% in the first quarter. JPMorgan Chase & Co. now owns 731,328 shares of the company’s stock worth $3,035,000 after acquiring an additional 83,009 shares in the last quarter. 47.12% of the stock is currently owned by hedge funds and other institutional investors.
Gamida Cell Price Performance
Gamida Cell (NASDAQ:GMDA – Get Rating) last released its quarterly earnings data on Tuesday, May 10th. The company reported ($0.34) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.34). During the same quarter in the previous year, the business earned ($0.34) earnings per share. On average, analysts predict that Gamida Cell will post -1.22 earnings per share for the current year.
Gamida Cell Company Profile
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia.
- Get a free copy of the StockNews.com research report on Gamida Cell (GMDA)
- 3 Large Caps With Bullish Chart Patterns
- Medtronic Stock Keeps Ticking Forward
- The Bull and Bear Case for Investing in AMD
- Occidental Petroleum Leads Exxon Mobil, Chevron Ahead Of Next Week’s Earnings
- Simpson Manufacturing Quietly Builds Foundations For Growth
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.